Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine

Jill A. Livengood, Charalambos D. Partidos, Kenneth Plante, Robert Seymour, Rodion Gorchakov, Laszlo Varga, Joanna Paykel, James Weger, Aurelia Haller, Dan T. Stinchcomb, Jorge Osorio, Scott Weaver

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recently, Chikungunya virus (CHIKV) re-emerged in Africa and spread in the Indian subcontinent, South East Asia and Italy causing millions of cases of debilitating arthritis and fever in endemic ppulations and in travellers highlighting its growing impact on public health. Currently, there are no licensed vaccines to protect against CHIKV available. We developed a novel live attenuated CHIKV vaccine by using a rational attenuation mechanism that also prevents the infection of mosquito vectors. The subgenomic promoter was inactivated using 13 synonymous mutations and an internal ribosome entry site (IRES) from encephalomyocarditis virus was inserted into a cDNA CHIKV clone to drive translation of the structural protein genes. This new CHIKV vaccine strain was highly stable, safe, immunogenic and protective in mice. Current pre-clinical development efforts are aiming to test this vaccine in non-human primates and complete the Investigational New Drug (IND)-enabling studies necessary to begin human clinical testing.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalProcedia in Vaccinology
Volume6
DOIs
StatePublished - 2012

Fingerprint

Chikungunya virus
Attenuated Vaccines
Vaccines
Encephalomyocarditis virus
Investigational Drugs
Far East
Protein Biosynthesis
Primates
Italy
Arthritis
Fever
Complementary DNA
Public Health
Clone Cells
Infection
Proteins

Keywords

  • Chikungunya
  • Immunogenicity
  • Interferon
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine. / Livengood, Jill A.; Partidos, Charalambos D.; Plante, Kenneth; Seymour, Robert; Gorchakov, Rodion; Varga, Laszlo; Paykel, Joanna; Weger, James; Haller, Aurelia; Stinchcomb, Dan T.; Osorio, Jorge; Weaver, Scott.

In: Procedia in Vaccinology, Vol. 6, 2012, p. 141-149.

Research output: Contribution to journalArticle

Livengood, JA, Partidos, CD, Plante, K, Seymour, R, Gorchakov, R, Varga, L, Paykel, J, Weger, J, Haller, A, Stinchcomb, DT, Osorio, J & Weaver, S 2012, 'Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine', Procedia in Vaccinology, vol. 6, pp. 141-149. https://doi.org/10.1016/j.provac.2012.04.019
Livengood, Jill A. ; Partidos, Charalambos D. ; Plante, Kenneth ; Seymour, Robert ; Gorchakov, Rodion ; Varga, Laszlo ; Paykel, Joanna ; Weger, James ; Haller, Aurelia ; Stinchcomb, Dan T. ; Osorio, Jorge ; Weaver, Scott. / Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine. In: Procedia in Vaccinology. 2012 ; Vol. 6. pp. 141-149.
@article{6a9cf780f6324d7e87fc5beeeaf06d1f,
title = "Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine",
abstract = "Recently, Chikungunya virus (CHIKV) re-emerged in Africa and spread in the Indian subcontinent, South East Asia and Italy causing millions of cases of debilitating arthritis and fever in endemic ppulations and in travellers highlighting its growing impact on public health. Currently, there are no licensed vaccines to protect against CHIKV available. We developed a novel live attenuated CHIKV vaccine by using a rational attenuation mechanism that also prevents the infection of mosquito vectors. The subgenomic promoter was inactivated using 13 synonymous mutations and an internal ribosome entry site (IRES) from encephalomyocarditis virus was inserted into a cDNA CHIKV clone to drive translation of the structural protein genes. This new CHIKV vaccine strain was highly stable, safe, immunogenic and protective in mice. Current pre-clinical development efforts are aiming to test this vaccine in non-human primates and complete the Investigational New Drug (IND)-enabling studies necessary to begin human clinical testing.",
keywords = "Chikungunya, Immunogenicity, Interferon, Vaccines",
author = "Livengood, {Jill A.} and Partidos, {Charalambos D.} and Kenneth Plante and Robert Seymour and Rodion Gorchakov and Laszlo Varga and Joanna Paykel and James Weger and Aurelia Haller and Stinchcomb, {Dan T.} and Jorge Osorio and Scott Weaver",
year = "2012",
doi = "10.1016/j.provac.2012.04.019",
language = "English (US)",
volume = "6",
pages = "141--149",
journal = "Procedia in Vaccinology",
issn = "1877-282X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine

AU - Livengood, Jill A.

AU - Partidos, Charalambos D.

AU - Plante, Kenneth

AU - Seymour, Robert

AU - Gorchakov, Rodion

AU - Varga, Laszlo

AU - Paykel, Joanna

AU - Weger, James

AU - Haller, Aurelia

AU - Stinchcomb, Dan T.

AU - Osorio, Jorge

AU - Weaver, Scott

PY - 2012

Y1 - 2012

N2 - Recently, Chikungunya virus (CHIKV) re-emerged in Africa and spread in the Indian subcontinent, South East Asia and Italy causing millions of cases of debilitating arthritis and fever in endemic ppulations and in travellers highlighting its growing impact on public health. Currently, there are no licensed vaccines to protect against CHIKV available. We developed a novel live attenuated CHIKV vaccine by using a rational attenuation mechanism that also prevents the infection of mosquito vectors. The subgenomic promoter was inactivated using 13 synonymous mutations and an internal ribosome entry site (IRES) from encephalomyocarditis virus was inserted into a cDNA CHIKV clone to drive translation of the structural protein genes. This new CHIKV vaccine strain was highly stable, safe, immunogenic and protective in mice. Current pre-clinical development efforts are aiming to test this vaccine in non-human primates and complete the Investigational New Drug (IND)-enabling studies necessary to begin human clinical testing.

AB - Recently, Chikungunya virus (CHIKV) re-emerged in Africa and spread in the Indian subcontinent, South East Asia and Italy causing millions of cases of debilitating arthritis and fever in endemic ppulations and in travellers highlighting its growing impact on public health. Currently, there are no licensed vaccines to protect against CHIKV available. We developed a novel live attenuated CHIKV vaccine by using a rational attenuation mechanism that also prevents the infection of mosquito vectors. The subgenomic promoter was inactivated using 13 synonymous mutations and an internal ribosome entry site (IRES) from encephalomyocarditis virus was inserted into a cDNA CHIKV clone to drive translation of the structural protein genes. This new CHIKV vaccine strain was highly stable, safe, immunogenic and protective in mice. Current pre-clinical development efforts are aiming to test this vaccine in non-human primates and complete the Investigational New Drug (IND)-enabling studies necessary to begin human clinical testing.

KW - Chikungunya

KW - Immunogenicity

KW - Interferon

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84860497408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860497408&partnerID=8YFLogxK

U2 - 10.1016/j.provac.2012.04.019

DO - 10.1016/j.provac.2012.04.019

M3 - Article

VL - 6

SP - 141

EP - 149

JO - Procedia in Vaccinology

JF - Procedia in Vaccinology

SN - 1877-282X

ER -